---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-22-000163"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:10:50.761577+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Zentalis appoints Jan Skvarka as Class III director, cures Nasdaq listing compliance

## Summary
- Jan Skvarka, Ph.D., M.B.A., appointed as Class III director effective September 9, 2022.
- Appointment to Audit and Nominating Committees cures Nasdaq Listing Rule 5605(c)(2) non-compliance.
- Initial term expires at 2023 annual meeting; receives standard director compensation.
- Granted RSUs covering 36,606 shares (value ~$1M) vesting over three years.
- Also eligible for annual RSU grant (~$500k) and committee retainers ($10k audit, $5k nominating).

## SEC filing metadata
- accession: 0001725160-22-000163
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000163/0001725160-22-000163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000163/zntl-20220909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-22-000163
- JSON: https://secwatch.observer/filing/0001725160-22-000163.json
- Plain text: https://secwatch.observer/filing/0001725160-22-000163.txt

## Key facts
- Executive change
  Jan Skvarka was appointed as Class III director at Zentalis Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On and effective September 9, 2022, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) appointed Jan Skvarka, Ph.D., M.B.A., as a Class III director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516022000163/0001725160-22-000163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.